Cyclacel Pharmaceuticals (CYCC) said Wednesday that it has completed the enrollment of 12 patients for cohort 8 of its phase 2 proof of concept study evaluating fadraciclib, a CDK2/9 inhibitor, in individuals with advanced solid tumors and lymphoma.
Cohort 8 is biomarker selected, with the participants preselected for CDKN2A and/or CDKN2B abnormalities, the company said.
Enrollment for cohort 5, involving patients with T-Cell Lymphoma, is ongoing, Cyclacel added.
The phase 2 study aims to assess the safety and efficacy of fadraciclib in up to eight patient groups, Cyclacel said, adding it expects to present data from the study at an oncology medical conference in October.
Shares of Cyclacel Pharmaceuticals were up 6% in recent Wednesday trading.
Price: 1.06, Change: +0.06, Percent Change: +6.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.